 |
|
|
|
|
|
Treatment |
|
Location |
|
Last Updated |
|
|
|
Details |
|
A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Durham, NC USA |
|
07/31/2008 |
|
|
|
|
|
Details |
|
A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Omaha, NE USA |
|
07/31/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme |
|
San Francisco, CA USA |
|
07/23/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Chicago, IL USA |
|
07/03/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Detroit, MI USA |
|
07/03/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Durham, NC USA |
|
07/03/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Charlottesville, VA USA |
|
07/03/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Cleveland, OH USA |
|
07/03/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Cleveland, OH USA |
|
07/03/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Hackensack, NJ USA |
|
07/03/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Syracuse, NY USA |
|
07/03/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Chicago, IL USA |
|
07/03/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Los Angeles, CA USA |
|
07/03/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Boston, MA |
|
07/03/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
New Haven, CT USA |
|
07/03/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Buffalo, NY USA |
|
07/03/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Salt Lake City, UT USA |
|
07/03/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Columbus, OH USA |
|
07/03/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Evanston, IL USA |
|
07/03/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Palo Alto, CA USA |
|
07/03/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
New York, NY USA |
|
07/03/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Philadelphia, PA USA |
|
07/03/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Houston, TX USA |
|
07/03/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Seattle, WA USA |
|
07/03/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
New York, NY USA |
|
07/03/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Jacksonville, FL USA |
|
07/03/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
San Francisco, CA USA |
|
07/03/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Saginaw, MI USA |
|
07/03/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Gainsville, FL USA |
|
07/03/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
San Antonio, TX USA |
|
07/03/2008 |
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Chicago, IL USA |
|
06/28/2008 |
|
|
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Detroit, MI USA |
|
06/28/2008 |
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Charlotte, NC USA |
|
06/28/2008 |
|
|
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Atlanta, GA USA |
|
06/28/2008 |
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Orlando, FL USA |
|
06/28/2008 |
|
|
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Birmingham, AL USA |
|
06/28/2008 |
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Saint Louis, MO USA |
|
06/28/2008 |
|
|
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Salt Lake City, UT USA |
|
06/28/2008 |
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
St. Louis, MO USA |
|
06/28/2008 |
|
|
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Birmingham, AL USA |
|
06/28/2008 |
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Duarte, CA USA |
|
06/28/2008 |
|
|
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Orlando, FL USA |
|
06/28/2008 |
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Tampa, FL USA |
|
06/28/2008 |
|
|
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Cambridge, MA USA |
|
06/28/2008 |
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Cambridge, MA USA |
|
06/28/2008 |
|
|
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Seattle, WA USA |
|
06/28/2008 |
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Duarte, CA USA |
|
06/28/2008 |
|
|
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Los Angeles, CA USA |
|
06/28/2008 |
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Chicago, IL USA |
|
06/28/2008 |
|
|
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Baltimore, MD USA |
|
06/28/2008 |
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Grand Rapids, MI USA |
|
06/28/2008 |
|
|
|
|
|
Details |
|
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma |
|
Dallas, TX USA |
|
06/28/2008 |
|
|
|
Details |
|
Study of a Drug [DCVax®-Brain] to Treat Newly Diagnosed GBM Brain Cancer |
|
Cincinnati, Oh USA |
|
06/04/2008 |
|
|
|
|
|
Details |
|
A Phase II Trial of Thalidomide in combination with Temozolomide or CPT-11 in patients with recurrent anaplastic gliomas or glioblastoma multiforme
|
|
Houston, TX USA |
|
04/16/2008 |
|
|
|
Details |
|
A Phase II Study of Rituximab and Temozolomide in Recurrent Primary CNS Lymphoma
|
|
Houston, TX USA |
|
04/16/2008 |
|
|
|
|
|
Details |
|
Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients with Recurrent Malignant Glioma
|
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
Details |
|
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
|
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase 2, 2-part, multicenter, open-label study to evaluate the safety, tolerability, and efficacy of CT-322 (Angiocept™) monotherapy and combination therapy with irinotecan in patients with recurrent glioblastoma multiforme
|
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Durham, NC USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Los Angeles, CA USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
New York, NY USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
San Antonio, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Bethesda, MD USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Madison, WI USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Pittsburgh, PA USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Boston, MA USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
Durham, NC USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
Los Angeles, CA USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
San Francisco, CA USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
Madison, WI USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
New York, NY USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
San Antonio, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
Bethesda, MD USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
Pittsburgh, PA USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
Boston, MA USA |
|
04/15/2008 |
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
New York, NY USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
Durham, NC USA |
|
04/15/2008 |
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
Los Angeles, CA USA |
|
04/15/2008 |
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
Bethesda, MD USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
Boston, MA |
|
04/15/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Houston, TX USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Phoenix, AZ USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Springfield, MO USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Greenville, SC USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Spartanburg, SC USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Galveston, TX USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Kalamazoo, MI USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
San Antonio, TX USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Akron, OH USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Kingsport, TN USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Newark, DE USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Jacksonville, FL USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Mobile, AL USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Sacramento, CA USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Columbus, GA USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Harvey, IL USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Saint Louis Park, MN USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Marlton, NJ USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Akron, OH USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Canton, OH USA |
|
04/11/2008 |
|
|
|
